Complement hyperactivation may cause atypical haemolytic uraemic syndrome - Gain-of-function mutations in factor B

Nephrology Dialysis Transplantation

Volumn 22, Issue 9, 2007, Pages 2452-2454

  Caprioli, Jessica ^a,c   Remuzzi, Giuseppe ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c Transplant Research Center   (Italy)

Author keywords

Complement factor B; HUS; Mutation

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C4; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; MEMBRANE COFACTOR PROTEIN; SERINE PROTEINASE;

ARTICLE; CLINICAL FEATURE; COMPLEMENT ACTIVATION; DISEASE PREDISPOSITION; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GRAFT FAILURE; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HETEROZYGOSITY; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA;

COMPLEMENT ACTIVATION; COMPLEMENT FACTOR B; COMPLEMENT PATHWAY, ALTERNATIVE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MUTATION;

EID: 34548455482     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm193     Document Type: Article

References (14)

1. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001; 60: 831-846
2. Caprioli J, Noris M, Brioschi S et al. Genetics of HUS: The impact of MCT, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108: 1267-1279
3. Richards A, Buddles MR, Donne RL et al. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet 2001; 68: 485-490
4. Fremeaux-Bacchi V, Moulton EA, Kavanagh D et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006; 17: 2017-2025
5. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 1035-1050
6. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 2007; 104: 240-245
7. Smith CA, Vogel CW, Muller-Eberhard HJ. MHC Class III products: An electron microscopic study of the C3 convertases of human complement. J Exp Med 1984; 159: 324-329
8. Bhattacharya AA, Lupher ML Jr, Staunton DE, Liddington RC. Crystal structure of the A domain from complement factor B reveals an integrin-tike open conformation. Structure 2004; 12: 371-378
9. Ponnuraj K, Xu Y, Macon K, Moore D, Volanakis JE, Narayana SV. Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase. Mol Cell 2004; 14: 17-28
10. Harris CL, Abbott RJ, Smith RA, Morgan BP, Lea SM. Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55). J Biol Chem 2005; 280: 2569-2578
11. Kavanagh D, Kemp EJ, Richards A et al. Does complement factor B have a role in the pathogenesis of atypical HUS? Mol Immunol 2006; 43: 856-859
12. Caprioli J, Bettinaglio P, Zipfel PF et al. The molecular basis of familial hemolytic uremic syndrome: Mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001; 12: 297-307
13. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005; 14: 703-712
14. Bresin E, Daina E, Noris M et al. Outcome of renal transplantation in patients with non-Shiga-toxin-associated hemolytic-uremic-syndrome: prognostic significance of genetic backgound. Clin J Am Soc Nephrol 2006; 1: 88-99